ClinicalTrials.gg
TerminatedNCT05470933Updated Sep 1, 2023

A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors

A Phase 1 interventional study of WJ01075 in Advanced Solid Tumors, sponsored by Suzhou Junjing BioSciences Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-01.

Sponsored by Suzhou Junjing BioSciences Co., Ltd. · Phase 1, Interventional, and Treatment

Why this study was terminated
Terminate the study and close the research center based on strategic changes in product development, unrelated to drug safety.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase I study to Investigate the safety and tolerability, DLT(Dose limited toxicity), MTD(Maximum tolerated dose), and RP2D(Recommended phase II dose) of WJ01075 tablets in patients with advanced malignant solid tumors, including phase Ia (dose escalation phase) and Phase Ib (dose expansion phase,cohort expansion phase).The study includes screening, treatment and follow-up periods.

In phase Ia, accelerated titration (the first two dose groups) and "3 + 3" combination (the subsequent dose group) were used for dose escalation.

In phase Ib, specific dose groups will be selected for dose expansion according to PK(Pharmacokinetics) and safety data of different dose groups in dose escalation phase.It is planned that SMC(Safety Monitoring Committee) will select one or more dose groups based on previous data for cohort expansion studies to further determine RP2D, safety tolerability and initial efficacy.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Suzhou Junjing BioSciences Co., Ltd. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with advanced malignant solid tumors clearly diagnosed pathologically and/or cytologically, who have failed to receive standard treatment, or who currently do not/or refuse standard treatment, or who are intolerant to standard treatment;
  2. Patient must have at least one as defined per v1.1;
  3. Aged between 18 and 75 (including 18 and 75), male and female patients;
  4. (ECOG) Performance Status (PS) score ≤1;
  5. ≥ 3 months;
  6. The functions of patients' major organs were basically normal, and the laboratory tests performed within 7 days prior to the first administration of study drugmet the following criteria, Patients must not have required a blood transfusion or growth factor support within 14 days before the examination:

    (AST) and Alanine Aminotransferase (ALT) ≤2.5 × (ULN); Total ≤ 1.5×ULN; (INR) ≤1.5; Creatinine ≤ 1.5 × ULN, and Rate (calculated by Cockcroft-Gault formula) ≥ 50 mL/min; (Hg) ≥ 90g/L; ≥ 100×10⋀9/L; (ANC) ≥ 1.5×10⋀9/L

  7. Fertile women must confirm a negative blood pregnancy test within 7 days prior to the first administration of study drug;All enrolled patients (both male and female) are required to use adequate and effective measures throughout the treatment period and within 3 months after the end of treatment;
  8. Those who voluntarily participate in the study and sign the written Form upon full informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with XPO1 inhibitors;
  2. Have a history of allergy to any component or of WJ010175 tablets;
  3. Patient with a primary other than the tumor treated in the study within 5 years prior to the first administration of study drug (exceptions include cured malignancies that did not recur within 3 years prior to enrollment;Basal cell and squamous cell carcinoma completely resected;Complete excision of any type of carcinoma in situ, etc.);
  4. Received other anti-tumor therapies, including but not limited to chemotherapy, radiotherapy, targeted therapy, immunotherapy and other anti-tumor therapies (such as anti-tumor traditional Chinese medicine), within 4 weeks or 5 half-life periods (whichever is longer) prior to the first administration of study drug;Or long-term treatment with potent CYP1A2 inhibitors, potent inducers and potent CYP3A4 inhibition;
  5. Thrombosis or embolism occurred within 6 months prior to the first administration of study drug;
  6. Received medium or major surgical treatment within 4 weeks prior to the first administration of study drug, other than diagnostic ;
  7. Any of the following conditions within 6 months prior to the first administration of study drug: New York Cardiology Association () > Grade II cardiac insufficiency, congestive heart failure, severe/unstable angina pectoris (symptoms of resting angina pectoris), myocardial infarction, arrhythmias requiring treatment, uncontrolled hypertension or hypertensive crisis or hypertensive encephalopathy;
  8. Adverse events and/or complications caused by previous treatment are not relieved to \< Level 2 (per V5.0);Any level of hair loss/pigmentation and long-term toxicity caused by other treatment, other than those that the investigator diagnosiss cannot be recovered and do not affect study administration or compliance and patient safety;
  9. Patient with central nervous system or tumors originating in the central nervous system;,
  10. Patient with grade ≥ 2 neuropathy (per NCI-CTCAE V5.0);
  11. Severe infections requiring antibiotic treatment within 14 days prior to the first administration of study drug ( > CTCAE Grade 2 ), such as severe pneumonia, bacteremia, infection complications requiring hospitalization;
  12. Uncontrolled pericardial effusion, pleural effusion or clinically obvious moderate to severe abdominal effusion during screening is defined as meeting the following criteria: having clinical symptoms and detectable thoracic and abdominal effusion during physical examination;Or in the screening process, the thoracoabdominal effusion needs to be punctured pumping liquid and/or intravenously administered;
  13. Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation;
  14. Patient has serious psychological or mental abnormalities affecting the compliance of the subjects to participate in the study;
  15. With active , or , or positive [HIV (+)] and syphilis antibody (+);Note: Hepatitis B virus surface Antigen (HBsAg) or core antibody (HBcAb) positive should be tested for HBV-DNA, and HBV-DNA should be below the lower limit of the reference range.Patients who are positive for Hepatitis C virus Antibody (HCV Ab) will be tested for HCV RNA and can be enrolled if they are below the .
  16. With Gastrointestinal dysfunction that may affect drug absorption (e.g., intestinal obstruction, inability to swallow tablets, malabsorption syndrome, uncontrollable nausea or vomiting, etc.);
  17. Pregnant or lactating women or men who still have reproductive needs;
  18. Other conditions that the investigator considers to be ineligible for inclusion, including but not limited to subjects whose body weight is less than ideal and who are expected to be significantly affected by weight change as determined by the investigator.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    WJ01075 tablets

    Once a week (QW).

    Drug: WJ01075

Interventions

  • DrugWJ01075

    Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and "3 + 3" combination (the subsequent dose group) were used for dose escalation. Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials.

06

What researchers measure

Primary outcomes

  1. Dose limited toxicity (DLT)

    incidence and severity of Dose limited toxicity(DLT);

    Time frame: 3 years

  2. Adverse event (AE)

    incidence and severity of adverse event (AE), Abnormal changes in laboratory and other tests of clinical significance;

    Time frame: 3 years

  3. Serious adverse event (SAE)

    incidence and severity of Serious adverse event (SAE);

    Time frame: 3 years

  4. Maximum tolerated dose (MTD)

    Maximum tolerated dose (MTD)

    Time frame: 2 years

  5. Recommended phase II dose (RP2D)

    Recommended phase II dose (RP2D)

    Time frame: 2 years

Secondary outcomes

  1. Objective response rate(ORR)

    Efficacy endpoints: Objective response rate(ORR) per RECIST v1.1

    Time frame: 2 years

  2. Duration of response (DOR)

    Efficacy endpoints: Duration of response (DOR) per RECIST v1.1

    Time frame: 2 years

  3. Disease control rate (DCR)

    Efficacy endpoints: Disease control rate (DCR) per RECIST v1.1

    Time frame: 2 years

  4. Time to response(TTR)

    Efficacy endpoints: Time to response(TTR) per RECIST v1.1

    Time frame: 2 years

  5. Progression-free survival (PFS)

    Efficacy endpoints: Progression-free survival (PFS) per RECIST v1.1

    Time frame: 2 years

  6. Overall survival (OS)

    Efficacy endpoints: Overall survival (OS) per RECIST v1.1

    Time frame: 2 years

  7. Peak time(Tmax)

    Pharmacokinetic (PK) parameter : Peak time(Tmax) after a single dose;

    Time frame: 2 years

  8. Maximum plasma concentration (Cmax)

    Pharmacokinetic (PK) parameter : Maximum plasma concentration (Cmax) after a single dose;

    Time frame: 2 years

  9. Clearance rate (CL/F)

    Pharmacokinetic (PK) parameter : Clearance rate (CL/F) after a single dose;

    Time frame: 2 years

  10. Apparent volume of distribution (Vd/F)

    Pharmacokinetic (PK) parameter : Apparent volume of distribution (Vd/F) after a single dose;

    Time frame: 2 years

  11. Area under blood concentration - time curve (AUC)

    Pharmacokinetic (PK) parameter : Area under blood concentration - time curve (AUC) after a single dose;

    Time frame: 2 years

  12. Elimination rate constant (λz)

    Pharmacokinetic (PK) parameter : Elimination rate constant (λz) after a single dose;

    Time frame: 2 years

  13. Elimination half-life time ( t1/2) and other parameters

    Pharmacokinetic (PK) parameter : Elimination half-life time ( t1/2) and other parameters after a single dose;

    Time frame: 2 years

  14. Steady state valley concentration(Cssmin)

    Pharmacokinetic (PK) parameter : Steady state valley concentration(Cssmin) after repeated administration;

    Time frame: 2 years

  15. Steady state peak concentration(Cssmax)

    Pharmacokinetic (PK) parameter : Steady state peak concentration(Cssmax) after repeated administration;

    Time frame: 2 years

  16. Average steady-state plasma concentration(Css-av)

    Pharmacokinetic (PK) parameter : Average steady-state plasma concentration(Css-av) after repeated administration;

    Time frame: 2 years

  17. Elimination half-life time ( t1/2)

    Pharmacokinetic (PK) parameter : Elimination half-life time ( t1/2) after repeated administration;

    Time frame: 2 years

  18. Steady state Area under blood concentration - time curve(AUCss)

    Pharmacokinetic (PK) parameter : Steady state Area under blood concentration - time curve(AUCss) after repeated administration;

    Time frame: 2 years

  19. Fluctuation coefficient (DF)

    Pharmacokinetic (PK) parameter : Fluctuation coefficient (DF) after repeated administration;

    Time frame: 2 years

  20. Steady-state distribution volume(Vss )

    Pharmacokinetic (PK) parameter : Steady-state distribution volume(Vss ) after repeated administration;

    Time frame: 2 years

  21. Accumulation coefficient (AR) and other parameters

    Pharmacokinetic (PK) parameter : Accumulation coefficient (AR) and other parameters after repeated administration;

    Time frame: 2 years

07

Study locations

1 site
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Apr 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2022
First posted
Jul 22, 2022
StartActual
Aug 23, 2022
Primary completionActual
Apr 18, 2023
CompletionActual
Apr 18, 2023
Last update
Sep 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05470933
Lead sponsor
Suzhou Junjing BioSciences Co., Ltd.
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Aug 23, 2022
Primary completion
Apr 18, 2023
Completion
Apr 18, 2023
Last update
Sep 1, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion